27.50

0.14% -0.2922

Gh Research Plc (GHRS)

Overview News Price History Option Chain Discussions Forecast

Gh Research Plc stock is traded at $27.50, with a volume of 193.93K. It is down -0.14% in the last 24 hours and down -8.32% over the past month. GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Previous Close:

$27.79

Open:

$27.77

24h Volume:

193.93K

Relative Volume:

0.70

Market Cap:

$1.89B

Revenue:

Net Income/Loss:

$-48.26M

P/E Ratio:

-34.81

EPS:

-0.7899

Net Cash Flow:

$-45.04M

1W Performance:

-1.14%

1M Performance:

-8.32%

6M Performance:

+73.66%

1Y Performance:

+106.79%

1-Day Range:

$26.46

$27.92

1-Week Range:

$26.46

$28.33

52-Week Range:

$11.83

$31.44

Gh Research Plc Stock (GHRS) Company Profile

Name

Gh Research Plc

Sector

Healthcare (1085)

Industry

Biotechnology (606)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

GHRS's Discussions on Twitter

Compare GHRS vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GHRS Gh Research Plc	27.50	1.91B	0	-48.26M	-45.04M	-0.7899
VRTX Vertex Pharmaceuticals Inc	521.64	134.06B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	804.50	83.43B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,004.64	63.00B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	137.22	56.02B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.21	44.44B	742.00K	-1.37B	-1.07B	-7.0731

Gh Research Plc Stock (GHRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-13-25	Initiated	Needham	Buy
Jun-04-25	Resumed	Cantor Fitzgerald	Overweight
Mar-13-25	Initiated	Guggenheim	Buy
Mar-07-25	Initiated	RBC Capital Mkts	Outperform
Feb-13-25	Initiated	Cantor Fitzgerald	Overweight
Aug-16-22	Initiated	H.C. Wainwright	Buy
Jun-16-22	Initiated	ROTH Capital	Buy

View All

Gh Research Plc Stock (GHRS) Latest News

Aug 31, 2026

(GHRS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Aug 31, 2026

Aug 30, 2026

GH Research (GHRS) Slides 2.48% to $27.94 as Shares Approach Key SupportBearish Pattern Stocks - vinanet.vn

Aug 30, 2026

Aug 21, 2026

Net margin % of GH Research Plc – HAM:1KA - TradingView

Aug 21, 2026

Net income before discontinued operations of GH Research Plc – HAM:1KA - TradingView

Aug 21, 2026

Aug 19, 2026

GH Research Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 19, 2026

Aug 17, 2026

How Rising Losses And Milestone Spending At GH Research (GHRS) Have Changed Its Investment Story - simplywall.st

Aug 17, 2026

GHRS Q2 2026 Earnings: Narrower Loss of -$0.23 Per Share Beats Estimates by 25.6%Earnings Trend Analysis - vinanet.vn

Aug 17, 2026

Aug 15, 2026

Zacks Research Upgrades GH Research (NASDAQ:GHRS) to Hold - MarketBeat

Aug 15, 2026

Aug 14, 2026

RA Capital discloses 7.1% GH Research PLC (GHRS) stake in Schedule 13G/A - Stock Titan

Aug 14, 2026

Lynx1 Capital Management (NASDAQ: GHRS) reports 19.3% stake in GH Research - Stock Titan

Aug 14, 2026

GH Research PLC (NASDAQ:GHRS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Aug 14, 2026

Aug 13, 2026

GH Research PLC Director Duncan Moore Granted 2,202 Share Options - Kalkine Media

Aug 13, 2026